The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Regeneron Announces November 2012 Investor Conference Presentations

Tuesday, November 06, 2012

Regeneron Announces November 2012 Investor Conference Presentations16:30 EST Tuesday, November 06, 2012TARRYTOWN, N.Y., Nov. 6, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences:Lazard Capital Markets 9th Annual Healthcare Conference at 11:00 a.m. Eastern Time on Tuesday, November 13, 2012 Credit Suisse Healthcare Conference at 9:30 a.m. Eastern Time (7:30 a.m. Mountain Time) on Wednesday, November 14, 2012 Piper Jaffray 24th Annual Healthcare Conference at 12:00 p.m. on Wednesday, November 28, 2012The sessions may be accessed through the Company's web site, www.regeneron.com, on the Events and Presentations page. Archived versions of the presentations will be available for thirty days after the live webcasts.  Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets three products in the United States, EYLEA® (aflibercept) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection for Subcutaneous Use; ZALTRAP is co-commercialized with Sanofi. Phase 3 studies are in progress with EYLEA in two additional indications and with product candidates sarilumab and REGN727.  Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia. Additional information and recent news releases are available on the Regeneron web site at www.regeneron.com.Contact Information:Manisha Narasimhan, Ph.D.Peter Dworkin                           Investor RelationsCorporate Communications 914-847-5126914.847.7640              manisha.narasimhan@regeneron.competer.dworkin@regeneron.com SOURCE Regeneron Pharmaceuticals, Inc.